Evaluation of efficacy and safety of gefitinib as monotherapy in Chinese patients with advanced non-small cell lung cancer and very poor performance statusReportar como inadecuado




Evaluation of efficacy and safety of gefitinib as monotherapy in Chinese patients with advanced non-small cell lung cancer and very poor performance status - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

BMC Research Notes

, 1:102

First Online: 28 October 2008Received: 18 April 2008Accepted: 28 October 2008DOI: 10.1186-1756-0500-1-102

Cite this article as: Wei, Z., Mengzhao, W., Li, Z. et al. BMC Res Notes 2008 1: 102. doi:10.1186-1756-0500-1-102

Abstract

BackgroundThis paper reports the outcome of gefitinib for Chinese advanced NSCLC patients with poor performance status PS at the Peking Union Medical College Hospital.

MethodsFrom Oct 2002 to Apr. 2006, 42 advanced NSCLC patients with PS 3-4 received gefitinib 250 mg-day treatment. Median survival MS were calculated using the Kaplan-Meier method and a Cox regression model was used to find main factors affecting MS.

ResultsAdverse events AEs were generally mild grade 1 and 2 and reversible. The most frequent AEs were rash 72.2% 26-42 and diarrhea 44.4% 26-42. The objective tumor response rate and stable disease rate were 40.5% and 26.2% respectively, and median survivalMS of all patients was 10.1 months 95% confidential interval CI, 3.4 ~ 16.8, and progression-free survivalPFS was 5.7 months 95% CI, 4.5 ~ 6.9. The MS were significantly related with objective response of gefitinib. Objective responses was significantly related with rashes induced with gefitinib.

ConclusionOur study suggest that treatment with gefitinib may be well tolerated and beneficial for Chinese patients with poor PS, and the safety and efficacy were similar to patients with good PS.

Electronic supplementary materialThe online version of this article doi:10.1186-1756-0500-1-102 contains supplementary material, which is available to authorized users.

Download fulltext PDF



Autor: Zhong Wei - Wang Mengzhao - Zhang Li - Li Longyun - Zhang Xiaotong

Fuente: https://link.springer.com/







Documentos relacionados